Sensus Healthcare (SRTS) Q4 2025: New CPT Codes Unlock 300% Reimbursement Surge, Redefining Growth Path
Dedicated reimbursement codes for Sensus's SRT technology mark a structural inflection, removing the two largest historical barriers: customer concentration and reimbursement uncertainty. With a clean balance sheet, expanded international momentum, and a more diversified customer base, Sensus enters 2026 positioned for profitability and operational leverage. The company’s commercial model is being rebuilt for scale, with new monetization options and a deliberate focus on direct sales and margin-rich international markets.
Summary
- Reimbursement Certainty Reshapes Adoption: Dedicated CPT codes eliminate ambiguity and open broader physician adoption channels.
- Customer Concentration Risk Mitigated: Direct sales and shared services reduce reliance on any single buyer.
- Profitability Targeted for 2026: Management expects improved operating leverage as international and domestic demand accelerates.
Business Overview
Sensus Healthcare develops and sells non-invasive superficial radiotherapy (SRT) systems used primarily for treating non-melanoma skin cancer. The company generates revenue through direct equipment sales, shared service agreements (Fair Deal Agreements, or FDA), leasing, and service contracts. Major segments include U.S. direct sales, international sales (notably China and Asia), and recurring service revenue, with the SRT and IG SRT platforms as core products. The business model is transitioning from customer concentration toward diversified, multi-channel monetization.
Performance Analysis
Q4 2025 results reflected a transitional period, with revenue sharply lower year-over-year due to the absence of sales to Sensus’s largest historical customer and a market-wide pause before the January 2026 CPT code rollout. Gross margin compressed, driven by lower volumes, higher service costs, and increased expenses tied to the FDA program. Operating expenses were mixed, as R&D and selling costs rose to support next-gen product development and commercial expansion, while G&A declined on lower professional fees.
Full-year 2025 financials echoed these trends: revenue fell on lower unit sales, but service revenue remained stable at roughly 10% of the mix. The company ended the year with $22.1 million in cash and no debt, having proactively built inventory for anticipated demand in 2026. Adjusted EBITDA turned negative, reflecting the transition and investment period, but management emphasized a return to profitability in 2026 as new reimbursement codes drive adoption and volumes.
- Revenue Mix Realignment: Direct sales and shared service placements are replacing outsized dependence on a single customer, with international sales (notably China, Taiwan, and Asia) gaining share.
- Margin Pressure from Transitional Costs: Gross margin dropped due to mix shift, higher service costs, and FDA-related expenses, but is expected to recover with volume scaling under the new reimbursement regime.
- Inventory Build Signals Anticipated Demand: Inventory rose to $14.6 million, reflecting confidence in 2026 system placements and readiness for rapid fulfillment.
Management’s explicit exclusion of its largest customer from 2026 guidance signals a reset in risk profile. Any contribution from that customer will be treated as upside rather than baseline expectation.
Executive Commentary
"With CPT codes for our SRT and IGSRT technology to treat non-melanoma skin cancer now being used and with a more diversified customer base emerging, both of these factors have been addressed."
Joe Sardano, Chairman and Chief Executive Officer
"Taken together, these developments position Census to scale more efficiently with improved visibility, stronger economics, and a broader set of monetization levers than at any point in the company's history."
Michael Sardano, President, Chief Commercial Officer and General Counsel
Strategic Positioning
1. Reimbursement Clarity as a Growth Catalyst
The award of exclusive CPT codes for SRT and IG SRT fundamentally shifts the commercial landscape. Physicians now have “black and white” reimbursement, removing ambiguity that previously slowed adoption. This change is expected to drive steady, multi-year adoption, especially among small and mid-sized practices.
2. Diversification of Customer Base and Monetization Models
Direct sales and Fair Deal Agreements (shared service programs) are now the primary growth engines, reducing historical customer concentration risk. The company is also expanding leasing and rental options, giving practices flexibility to match their financial and operational needs.
3. International Expansion and Margin Leverage
International sales, particularly in China and broader Asia, are delivering both growth and higher margins due to lower installation and servicing costs. New regulatory certifications (MDSAP) are opening additional markets such as Japan, South Korea, and Brazil, where regulatory clearance is expected in 2026.
4. Commercial Organization Scaling and Targeted Market Education
Sensus is expanding its sales force and refining its trade show strategy to focus on high-yield events and decision-maker engagement. The goal is to accelerate lead conversion and maximize ROI on commercial spend as the market absorbs the impact of reimbursement certainty.
5. Product Development and Pipeline Readiness
R&D spend increased to advance next-generation systems (e.g., Sentinel 2.0) and support ongoing FDA and reimbursement initiatives. The company is preparing for broader rollouts as new products reach commercialization.
Key Considerations
Sensus enters 2026 with a fundamentally different risk and opportunity profile, shaped by reimbursement clarity, a clean balance sheet, and a more flexible commercial model. The strategic focus is on scaling efficiently, capturing international opportunity, and leveraging new monetization channels.
Key Considerations:
- Reimbursement-Driven Demand Acceleration: New CPT codes are expected to drive adoption across a wider range of practice sizes, with rapid break-even economics for buyers.
- Customer Mix Shift Reduces Revenue Volatility: Direct sales and shared services now anchor growth, with large-customer orders treated as upside rather than baseline.
- International Markets as a Margin Lever: Sales to China, Taiwan, and Asia are expanding, with additional upside from Brazil and the Middle East pending regulatory approvals.
- Inventory and Cash Provide Growth Flexibility: Sensus is well-capitalized to support system placements and working capital needs as demand ramps.
- Sales Organization Investment: Headcount and market education spend are rising to accelerate pipeline conversion and capitalize on new reimbursement economics.
Risks
Execution risk remains around the pace of adoption as the market digests new reimbursement codes and as Sensus transitions to a more diversified customer base. International expansion depends on successful navigation of regulatory hurdles, particularly in Brazil and Japan. The company’s profitability target for 2026 is contingent on volume recovery and margin improvement, and any delays in pipeline conversion or international approvals could impact financial trajectory. Ongoing product development, such as TDI and Sentinel 2.0, faces regulatory and commercialization uncertainty.
Forward Outlook
For Q1 2026, Sensus guided to:
- System shipments exceeding Q4 2025 levels, even without contribution from the largest customer
- Continued international growth, especially in Asia and pending markets like Brazil
For full-year 2026, management expects:
- Profitability on a full-year basis
- Steady adoption as reimbursement certainty drives new placements
Management highlighted several factors that will shape 2026:
- Sales force expansion and targeted market education to accelerate adoption
- Operational discipline and selective commercial investment to maximize ROI
Takeaways
Sensus Healthcare is at a structural inflection point, with reimbursement certainty and a diversified customer base setting the stage for scalable growth and improved margin leverage.
- Reimbursement Codes Transform Adoption Trajectory: The new CPT codes remove the largest historical barrier, enabling broader market penetration and a more predictable revenue base.
- Risk Profile Improved by Customer Diversification: Direct sales and shared services now anchor the model, reducing exposure to single-customer volatility.
- Profitability and International Expansion in Focus: Investors should watch for progress on international regulatory approvals and the pace of U.S. adoption as key drivers of 2026 performance.
Conclusion
Sensus Healthcare’s Q4 2025 results mark the end of a transitional phase and the beginning of a new era defined by reimbursement certainty and operational flexibility. With a clean balance sheet, robust inventory, and a retooled commercial model, Sensus is positioned to deliver profitable growth in 2026 and beyond.
Industry Read-Through
The structural impact of dedicated reimbursement codes for SRT technology is a clear signal for medtech peers: reimbursement clarity can rapidly unlock latent demand and reduce sales cycle friction. Companies with non-invasive or alternative therapies should prioritize payer engagement and reimbursement strategy as a core growth lever. International margin dynamics highlight the value of regulatory diversification and early entry into high-growth Asian and LATAM markets. The Sensus case also underscores the importance of risk mitigation through customer diversification and multi-channel monetization, especially for device makers historically reliant on a few large buyers.